Gemfibrozil greatly increases plasma concentrations of cerivastatin

Clinical Pharmacology and Therapeutics

Volumn 72, Issue 6, 2002, Pages 685-691

  Backman, Janne T ^a   Kyrklund, Carl ^a   Neuvonen, Mikko ^a   Neuvonen, Pertti J ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

CERIVASTATIN; GEMFIBROZIL; MEVINOLIN; PLACEBO; SIMVASTATIN; STATIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG ELIMINATION; ENZYME INHIBITION; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; MALE; MYOPATHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHABDOMYOLYSIS; SKELETAL MUSCLE;

ADMINISTRATION, ORAL; ADULT; ANTILIPEMIC AGENTS; AREA UNDER CURVE; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; FEMALE; GEMFIBROZIL; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; PYRIDINES; REFERENCE VALUES; RHABDOMYOLYSIS;

EID: 0036918664     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1067/mcp.2002.128469     Document Type: Article

References (35)

1. Farmer JA. Learning from the cerivastatin experience. Lancet 2001;358:1383-5.
2. Staffa JA, Chang J, Green L. Cerivastatin and reports of fatal rhabdomyolysis. N Engl J Med 2002;346:539-40.
3. Pogson GW, Kindred LH, Carper BG. Rhabdomyolysis and renal failure associated with cerivastatin-gemfibrozil combination therapy [case report]. Am J Cardiol 1999;83:1146.
4. Miller DB, Spence JD. Clinical pharmacokinetics of fibric acid derivatives (fibrates). Clin Pharmacokinet 1998;34:155-62.
5. Rhabdomyolysis seen with simvastatin 160 mg. Reactions 1997;653:2.
6. Bradford RH, Shear CL, Chremos AN, Dujovne C, Downton M, Franklin FA, et al. Expanded Clinical Evaluation of Lovastatin (EXCEL) study results. I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia. Arch Intern Med 1991;151:43-9.
7. Dujovne CA, Chremos AN, Pool JL, Schnaper H, Bradford RH, Shear CL, et al. Expanded clinical evaluation of lovastatin (EXCEL) study results. IV. Additional perspectives on the tolerability of lovastatin. Am J Med 1991;91:25S-30S.
8. Neuvonen PJ, Jalava KM. Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid. Clin Pharmacol Ther 1996;60:54-61.
9. Neuvonen PJ, Kantola T, Kivistö KT. Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole. Clin Pharmacol Ther 1998;63:332-41.
10. Arnadottir M, Eriksson LO, Thysell H, Karkas JD. Plasma concentration profiles of simvastatin 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitory activity in kidney transplant recipients with and without ciclosporin. Nephron 1993;65:410-3.
11. Welker HA, Wiltshire H, Bullingham R. Clinical pharmacokinetics of mibefradil. Clin Pharmacokinet 1998;35:405-23.
12. Gruer PJ, Vega JM, Mercuri MF, Dobrinska MR, Tobert JA. Concomitant use of cytochrome P450 3A4 inhibitors and simvastatin. Am J Cardiol 1999;84:811-5.
13. Mück W. Clinical pharmacokinetics of cerivastatin. Clin Pharmacokinet 2000;39:99-116.
14. Boberg M, Angerbauer R, Fey P, Kanhai WK, Karl W, Kern A, et al. Metabolism of cerivastatin by human liver microsomes in vitro: Characterization of primary metabolic pathways and of cytochrome P450 isozymes involved. Drug Metab Dispos 1997;25:321-31.
15. Mack W. Rational assessment of the interaction profile of cerivastatin supports its low propensity for drug interactions. Drugs 1998;56(Suppl 1):15-23.
16. Kantola T, Kivistö KT, Neuvonen PJ. Effect of itraconazole on cerivastatin pharmacokinetics. Eur J Clin Pharmacol 1999;54:851-5.
17. Mück W, Ochmann K, Rohde G, Unger S, Kuhlmann J. Influence of erythromycin pre- and co-treatment on single-dose pharmacokinetics of the HMG-CoA reductase inhibitor cerivastatin. Eur J Clin Pharmacol 1998;53:469-73.
18. Jemal M, Rao S, Salahudeen I, Chen BC, Kates R. Quantitation of cerivastatin and its seven acid and lactone biotransformation products in human serum by liquid chromatography-electrospray tandem mass spectrometry. J Chromatogr B Biomed Sci Appl 1999;736:19-41.
19. Hengy H, Kölle EU. Determination of gemfibrozil in plasma by high performance liquid chromatography. Arzneimittelforschung 1985;35:1637-9.
20. Backman JT, Kyrklund C, Kivistö KT, Wang JS, Neuvonen PJ. Plasma concentrations of active simvastatin acid are increased by gemfibrozil. Clin Pharmacol Ther 2000;68:122-9.
21. Wen X, Wang JS, Backman JT, Kivistö KT, Neuvonen PJ. Gemfibrozil is a potent inhibitor of human cytochrome P450 2C9. Drug Metab Dispos 2001;29:1359-61.
22. Kyrklund C, Backman JT, Kivistö KT, Neuvonen M, Laitila J, Neuvonen PJ. Plasma concentrations of active lovastatin acid are markedly increased by gemfibrozil but not by bezafibrate. Clin Pharmacol Ther 2001;69:340-5.
23. Niemi M, Neuvonen PJ, Kivistö KT. Effect of gemfibrozil on the pharmacokinetics and pharmacodynamics of glimepiride. Clin Pharmacol Ther 2001;70:439-45.
24. Spence JD, Munoz CE, Hendricks L, Latchinian L, Khouri HE. Pharmacokinetics of the combination of fluvastatin and gemfibrozil. Am J Cardiol 1995;76:80A-3A.
25. Prueksaritanont T, Zhao JJ, Ma B, Roadcap BA, Tang C, Qiu Y, et al. Mechanistic studies on metabolic interactions between gemfibrozil and statins. J Pharmacol Exp Ther 2002;301:1042-51.
26. Prueksaritanont T, Subramanian R, Fang X, Ma B, Qiu Y, Lin JH, et al. Glucuronidation of statins in animals and humans: A novel mechanism of statin lactonization. Drug Metab Dispos 2002;30:505-12.
27. Górriz JL, Sancho A, Lopez-Martin JM, Alcoy E, Catalán C, Pallardo LM. Rhabdomyolysis and acute renal failure associated with gemfibrozil therapy. Nephron 1996;74:437-8.
28. Magarian GJ, Lucas LM, Colley C. Gemfibrozil-induced myopathy. Arch Intern Med 1991;151:1873-4.
29. Shek A, Ferrill MJ. Statin-fibrate combination therapy. Ann Pharmacother 2001;35:908-17.
30. Murdock DK, Murdock AK, Murdock RW, Olson KJ, Frane AM, Kersten ME, et al. Long-term safety and efficacy of combination gemfibrozil and HMG-CoA reductase inhibitors for the treatment of mixed lipid disorders. Am Heart J 1999;138(1 Pt 1):151-5.
31. Hargreaves IP, Heales S. Statins and myopathy. Lancet 2002;359:711-2.
32. Åberg F, Appelkvist EL, Broijersen A, Eriksson M, Angelin B, Hjemdahl P, et al. Gemfibrozil-induced decrease in serum ubiquinone and alpha- and gamma-tocopherol levels in men with hyperlipidaemia. Eur J Clin Invest 1998;28:235-42.
33. Laaksonen R, Jokelainen K, Sahi T, Tikkanen MJ, Himberg JJ. Decreases in serum ubiquinone concentrations do not result in reduced levels in muscle tissue during short-term simvastatin treatment in humans. Clin Pharmacol Ther 1995;57:62-6.
34. Laaksonen R, Jokelainen K, Laakso J, Sahi T, Härkonen M, Tikkanen MJ, et al. The effect of simvastatin treatment on natural antioxidants in low-density lipoproteins and high-energy phosphates and ubiquinone in skeletal muscle. Am J Cardiol 1996;77:851-4.
35. Pan WJ, Gustavson LE, Achari R, Rieser MJ, Ye X, Gutterman C, et al. Lack of a clinically significant pharmacokinetic interaction between fenofibrate and pravastatin in healthy volunteers. J Clin Pharmacol 2000;40:316-23.